Influenza B Infections - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Influenza B Infections - Pipeline Review, H2 2016’, provides an overview of the Influenza B Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza B Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Influenza B Infections

The report reviews pipeline therapeutics for Influenza B Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Influenza B Infections therapeutics and enlists all their major and minor projects

The report assesses Influenza B Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Influenza B Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Influenza B Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Influenza B Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc.

Altravax, Inc.

Aphios Corporation

BioClonetics Immunotherapeutics, Inc.

ContraFect Corporation

Humabs BioMed SA

Johnson & Johnson

Medicago Inc.

MedImmune, LLC

Mucosis B.V.

Sanofi Pasteur ...

AbbVie Inc.

Altravax, Inc.

Aphios Corporation

BioClonetics Immunotherapeutics, Inc.

ContraFect Corporation

Humabs BioMed SA

Johnson & Johnson

Medicago Inc.

MedImmune, LLC

Mucosis B.V.

Sanofi Pasteur SA

Vaxart, Inc.

Zydus Cadila Healthcare Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Influenza B ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Influenza B Infections Overview 8

Therapeutics Development 9

Pipeline Products for Influenza B Infections - Overview 9

Pipeline Products for Influenza B Infections - Comparative Analysis 10

Influenza B Infections - Therapeutics under Development by Companies 11

Influenza B Infections - Therapeutics under Investigation by Universities/Institutes 12

Influenza B Infections - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Influenza B Infections - Products under Development by Companies 16

Influenza B Infections - Products under Investigation by Universities/Institutes 17

Influenza B Infections - Companies Involved in Therapeutics Development 18

AbbVie Inc. 18

Altravax, Inc. 19

Aphios Corporation 20

BioClonetics Immunotherapeutics, Inc. 21

ContraFect Corporation 22

Humabs BioMed SA 23

Johnson & Johnson 24

Medicago Inc. 25

MedImmune, LLC 26

Mucosis B.V. 27

Sanofi Pasteur SA 28

Vaxart, Inc. 29

Zydus Cadila Healthcare Limited 30

Influenza B Infections - Therapeutics Assessment 31

Assessment by Monotherapy Products 31

Assessment by Combination Products 32

Assessment by Target 33

Assessment by Mechanism of Action 35

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

AL-18 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

APP-0205 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

APP-309 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

CF-403 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

CR-8033 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

CR-8071 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

CR-9114 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Fluad (quadrivalent) - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

FluGEM - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

influenza [serotype B] vaccine - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

influenza [serotypes A, B] (split virion, tetravalent) vaccine - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

influenza [serotypes A, B] (virus like particle) vaccine - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Monoclonal Antibody for Influenza B - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Monoclonal Antibody for Influenza B Infections - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

VXABYW-10 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Influenza B Infections - Dormant Projects 66

Influenza B Infections - Discontinued Products 67

Influenza B Infections - Product Development Milestones 68

Featured News & Press Releases 68

Dec 17, 2015: Vaxart Announces Enrollment of First Patient in Influenza B Phase 1 Trial 68

Mar 11, 2011: Sanofi Pasteur And Daiichi Sankyo Announce Voluntary Recall Of Hemophilus Influenza Type B Conjugate Vaccine 69

Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children 69

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 70

Disclaimer 71

List of Tables

List of Tables

Number of Products under Development for Influenza B Infections, H2 2016 9

Number of Products under Development for Influenza B Infections - ...

List of Tables

Number of Products under Development for Influenza B Infections, H2 2016 9

Number of Products under Development for Influenza B Infections - Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Influenza B Infections - Pipeline by AbbVie Inc., H2 2016 18

Influenza B Infections - Pipeline by Altravax, Inc., H2 2016 19

Influenza B Infections - Pipeline by Aphios Corporation, H2 2016 20

Influenza B Infections - Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016 21

Influenza B Infections - Pipeline by ContraFect Corporation, H2 2016 22

Influenza B Infections - Pipeline by Humabs BioMed SA, H2 2016 23

Influenza B Infections - Pipeline by Johnson & Johnson, H2 2016 24

Influenza B Infections - Pipeline by Medicago Inc., H2 2016 25

Influenza B Infections - Pipeline by MedImmune, LLC, H2 2016 26

Influenza B Infections - Pipeline by Mucosis B.V., H2 2016 27

Influenza B Infections - Pipeline by Sanofi Pasteur SA, H2 2016 28

Influenza B Infections - Pipeline by Vaxart, Inc., H2 2016 29

Influenza B Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 30

Assessment by Monotherapy Products, H2 2016 31

Assessment by Combination Products, H2 2016 32

Number of Products by Stage and Target, H2 2016 34

Number of Products by Stage and Mechanism of Action, H2 2016 35

Number of Products by Stage and Route of Administration, H2 2016 37

Number of Products by Stage and Molecule Type, H2 2016 39

Influenza B Infections - Dormant Projects, H2 2016 66

Influenza B Infections - Discontinued Products, H2 2016 67

List of Figures

List of Figures

Number of Products under Development for Influenza B Infections, H2 2016 9

Number of Products under Development for Influenza B Infections - ...

List of Figures

Number of Products under Development for Influenza B Infections, H2 2016 9

Number of Products under Development for Influenza B Infections - Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 31

Assessment by Combination Products, H2 2016 32

Number of Products by Targets, H2 2016 33

Number of Products by Stage and Targets, H2 2016 33

Number of Products by Routes of Administration, H2 2016 36

Number of Products by Stage and Routes of Administration, H2 2016 36

Number of Products by Molecule Types, H2 2016 38

Number of Products by Stage and Molecule Types, H2 2016 38

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports